key: cord-0863731-1anehgsz authors: Fang, C.; Garzillo, G.; Batohi, B.; Teo, J. T.; Berovic, M.; Sidhu, P.; Robbie, H. title: Pulmonary Thromboembolic Disease in Patients with COVID-19 Undergoing Computed Tomography Pulmonary Angiography (CTPA): Incidence and Relationship with Pulmonary Parenchymal Abnormalities date: 2020-06-02 journal: nan DOI: 10.1101/2020.06.01.20118505 sha: 688dc87c2d31277dbd69b3e5d9a73d0b786711bb doc_id: 863731 cord_uid: 1anehgsz Purpose This study aims to report the incidence, severity and extent of pulmonary thromboembolic disease (PTD) in patients with confirmed COVID-19 who have undergone CT pulmonary angiography (CTPA) in a tertiary centre. Materials and Methods This is a retrospective analysis of all patients undergoing CTPA between 23rd March 2020 and 19th April 2020 in a tertiary centre. The presence of PTD, location and involved pulmonary lobes were documented. The pattern and extent of pulmonary parenchymal abnormalities including the presence of fibrosis, lymph node enlargement and pleural effusion were evaluated by two experienced observers independently and consensus was achieved for the most disparate results. Inter-observer agreement was assessed using Kappa statistics. Student t-test, Chi square and Mann-Whitney U tests were used to compare imaging features between PTD and non-PTD sub-groups. Results During the study period, 2157 patients were confirmed with COVID-19, 297/2157 (13.8%) had CT imaging, 100/2157 (4.6%) were CTPA studies, 93 studies were analysed, excluding sub-optimal studies. Overall incidence of PTD was 41/93 (44%) with a third of patients showing segmental and subsegmental PTD (n=28/93, 30%,). D-dimer was elevated in 90/93 (96.8%) of cases. High Wells score did not differentiate between PE and non-PE groups (p=0.801). The inter-observer agreement was fair (Kappa=0.659) for parenchymal pattern and excellent (Kappa = 0.816) for severity. Lymph node enlargement was found in 34/93 of cases (36.6%) with 29/34 (85.3%) showing no additional source of infection. Fibrosis was seen in 16/93 (17.2%) of cases, mainly demonstrating fibrotic organising pneumonia. Conclusion There is a high incidence of PTD in COVID -19 patients undergoing CTPA, complicated by lack of a valid risk stratification tool. Our data indicates a much higher suspicion of PTD is needed in severe COVID-19 patients. The concomitant presence of fibrotic features on CT indicates the need for follow-up for evaluation of chronic pulmonary complications. evidence points towards hyperinflammation resulting in a vascular disease within the lungs that is primarily characterised by thrombotic microangiopathy [19, 20] . Recently published data in a small cohort of hospitalised patients with severe COVID-19 suggests up to 40% incidence of pulmonary thromboembolic disease (PTD) [21, 22] . The recent report from the national institute for Public Health of the Netherlands concluded that thrombotic state can occur in a substantial percentage of COVID-19 patients but highlighted the paucity of data on the prevalence of PTD [23] . In this study, we aim to report the incidence as well as severity and extent of PTD in patients with confirmed COVID-19 who have undergone CTPA imaging in a tertiary centre. The secondary aim of this study is 1; to assess the effectiveness of British Society of Thoracic Imaging (BSTI) current guidance on pattern and extent of lung parenchymal abnormalities in COVID-19 [11] and 2; to assess whether there is any difference in the patterns and severity of disease on CT in COVID-19 patients with and without PTD. CTPA protocol COVID-19 and mild, moderate and severe respectively based on BSTI guidelines [11] ( Table 1) . The CT severity was defined as mild if up to 3 focal abnormality of 3cm in maximum diameter. Severity of PTD was classified as subsegmental, segmental, lobar, main and saddle. The extent of PTD was documented based on the number of pulmonary lobes involved (between 1 -6); with lingula considered a separate lobe. Fibrosis was considered present if two of the following were observed: traction bronchiectasis within the areas of parenchymal abnormality, volume loss and architectural distortion as per Fleischner Society glossary of terms [25] . The patterns of pulmonary fibrosis on CT were categorised into fibrotic organising pneumonia or acute respiratory distress syndrome (ARDS), also based on Fleischner Society glossary of terms [25] . Intrathoracic lymph nodes were considered enlarged if they measured >10mm or > 3mm in short axis diameter for mediastinal and hilar lymph nodes respectively [26] . Right heart strain on CT was defined as pulmonary artery diameter to ascending thoracic aorta ratio >1 [27] . Statistical analysis was performed by using SPSS software (IBM, Chicago, version 23); P values < .05 were considered to indicate statistical significance. Continuous variables were reported as mean ±standard deviation or median (interquartile range) as appropriate. Kappa statistics were used to assess inter-observer agreement with the level of agreement classified as: poor (kappa <0.40), fair (0.4